Safety concerns prompt Ipsen to pull Tazverik from market Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

#Ipsen is voluntarily withdrawing its EZH2 inhibitor #Tazverik from sale after a clinical trial suggested a link with #secondarybloodcancers.